Group 1 - The core point of the news is that Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock price increase of 5.56%, reaching 57.00 CNY per share, with a total market capitalization of 4.503 billion CNY as of January 7 [1] - The company, established on February 22, 2013, and listed on May 17, 2022, focuses on technology development, transfer, consultation, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - From the perspective of fund holdings, the Chuangjin Hexin Fund has a significant position in Prasis, with its Chuangjin Hexin Health Mixed A Fund (013348) holding 121,000 shares, representing 4.56% of the fund's net value, making it the tenth largest holding [2] - The Chuangjin Hexin Health Mixed A Fund was established on January 26, 2022, with a current scale of 47.4529 million CNY, and has achieved a year-to-date return of 5.36%, ranking 833 out of 8,823 in its category [2] Group 3 - The fund manager of Chuangjin Hexin Health Mixed A Fund is Pi Jinsong, who has been in the position for 7 years and 71 days, managing assets totaling 900 million CNY, with the best fund return during his tenure being 92.69% and the worst being -49.36% [3]

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is located in Futian District, Shenzhen, Guangdong Province, and was established on November 3, 1998. The company was listed on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1]. - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1]. Stock Performance - On September 19, Xinlitai's stock fell by 5.14%, closing at 51.70 CNY per share, with a trading volume of 301 million CNY and a turnover rate of 0.51%. The total market capitalization is 57.636 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Chuangjin Hexin has a significant position in Xinlitai. The Chuangjin Hexin Health Mixed A Fund (013348) reduced its holdings by 22,500 shares in the second quarter, holding a total of 138,500 shares, which represents 5.99% of the fund's net value, ranking as the ninth largest holding [2]. - The Chuangjin Hexin Health Mixed A Fund was established on January 26, 2022, with a latest scale of 40.2061 million CNY. Year-to-date returns are 48.83%, ranking 1032 out of 8172 in its category, while the one-year return is 53.87%, ranking 2857 out of 7980. Since its inception, the fund has experienced a loss of 15.48% [2]. Fund Manager Information - The fund manager of Chuangjin Hexin Health Mixed A Fund is Pi Jinsong, who has been in the position for 6 years and 326 days. The total asset size of the fund is 621 million CNY. During his tenure, the best fund return was 130.01%, while the worst return was -49.36% [3].